Market News & Trends
Kamada Receives Additional Milestone Payment Under Exclusive Supply & Distribution Agreement
Kamada Ltd. recently announced the receipt of an undisclosed additional milestone payment under the supply and distribution agreement with Shire for GLASSIA, Kamada’s intravenous (IV)…
Aclaris Therapeutics Announces Issuance of New US Patent for Topical Solutions
Aclaris Therapeutics, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,675,639 covering the formulation and methods of…
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial
Threshold Pharmaceuticals, Inc. recently announced that the University of Texas MD Anderson Cancer Center has dosed the first patient in a Phase 1 immunotherapy clinical…
Nobilis Therapeutics Receives Patent Covering Treatment of Psychiatric Disorders With Noble Gases
Nobilis Therapeutics recently announced that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of Harvard University) has received a notice…
Rentschler Biotechnologie & Rentschler Fill Solutions Announce Strategic Partnership
Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH recently announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for…
Q BioMed Finalizes License Agreement for Novel Liver Cancer Treatment
Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the…
Nemera Announces Research Agreement With UFRT for New Nasal Drug Delivery Treatments
Nemera and the Research Center for Respiratory Diseases (CEPR) of Tours University (INSERM U1100) recently announced they have joined forces in a partnership to enhance…
Calithera Biosciences Announces FDA Fast Track Designation
Calithera Biosciences, Inc. recently announced that the US FDA has granted Fast Track designation to CB-839 in combination with everolimus, for the treatment of patients…
Cell Design Labs Announces Issuance of Patent for Chimeric Notch Receptor
Cell Design Labs, Inc. recently announced the issuance of US Patent No. 9,670,281, titled Binding-triggered transcriptional switches and the methods of use thereof. This patent,…
Mateon Therapeutics Receives FDA Fast Track Designation
Mateon Therapeutics, Inc. recently announced that the US FDA has granted Fast Track designation to the company’s product candidate OXi4503 for the treatment of acute…
Aptevo Therapeutics Highlights ADAPTIR™ Protein Therapeutic Platform
Aptevo Therapeutics Inc. recently announced that aspects of its ADAPTIR protein therapeutic platform were showcased recently at the Americas Antibody Congress 2017 in San Diego…
Protalix BioTherapeutics Announces Phase II Clinical Trial Results
Protalix BioTherapeutics, Inc. recently announced that Phase II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of Cystic Fibrosis (CF)…
COPD Market Set to Hit $14.1 Billion by 2025
The chronic obstructive pulmonary disease (COPD) space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, is…
IntelGenx Receives Patent for Topical Oral Film Technology
IntelGenx Corp., a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm…
Lubrizol Invests $60 Million to Expand Particle Sciences, Vesta & Other Facilities
The Lubrizol Corporation recently announced its LifeSciences business continues to invest in its key capabilities through a variety of planned expansions. During this latest phase,…
Envigo Announces Successful AAALAC Accreditation
Envigo has announced that its Research Models and Services (RMS) facility in Hyderabad, India, has been granted full accreditation by the Association for Assessment and…
KaloBios Submits IND Application to FDA
KaloBios Pharmaceuticals, Inc. recently announced it has submitted an Investigational New Drug (IND) application to the US FDA for benznidazole for the treatment of Chagas…
Bayer Receives FDA Approval of myBETAapp & BETACONNECT Navigator
Bayer recently announced that the US FDA has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator. With this software in…
GeneCentric Therapeutics Appoints New CBO; Advances Drug Development Platform
GeneCentric Therapeutics, Inc. recently announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors. In…
Celyad Obtains Additional US Patent for Cancer Treatment Based on TCR-Deficient Allogeneic CAR-T cells
Celyad recently announced the issuance of United States Patent No. 9,663,763 relating to Celyad’s method of treating cancer by administering allogeneic primary human T cells…
